Literature DB >> 25915141

Maternal methadone treatment and neonatal abstinence syndrome.

William F Liu1, Kultar Singh1, Mohamed Faisal1, Shuang Li2.   

Abstract

OBJECTIVE: This article aims to describe neonatal outcomes, clinical correlates, and the rate for neonatal abstinence syndrome (NAS) for women on methadone maintenance therapy.
METHODS: This study is a retrospective review, which includes 119 mothers and 120 live newborns.
RESULTS: Methadone mothers tends to be white, single, on government insurance, with increased tobacco use (73%) and hepatitis C (11%). Prematurity increased (28%), and the term infant had a higher risk for admission for respiratory symptoms (22, 7%, p < 0.001). Overall, 78% newborns developed NAS, with the onset of symptoms 4.3 ± 2.9 days, and average length of stay of 36.7 ± 26.4 days. There was a decreased overall gestational age for those infants who did not have NAS (36, 38 weeks, p = 0.04). Overall, 56% had possible illicit drug supplementation. Self-reporting had a 59% negative predictive value with a positive drug screen. No difference in maternal methadone dosage and newborns with and without NAS. Increasing gestational age will increase the odds for NAS.
CONCLUSIONS: Newborns are at higher risk for prematurity and admission for respiratory symptoms. Utilizing a 7-day observation period, 78% of newborns were diagnosed with NAS with a mean onset of symptoms of 4.3 days. There was no difference in methadone dosage between babies with and without NAS. Increasing gestational age increases the risk for NAS. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25915141     DOI: 10.1055/s-0035-1549218

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  5 in total

Review 1.  Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects.

Authors:  Irma Convertino; Alice Capogrosso Sansone; Alessandra Marino; Maria T Galiulo; Stefania Mantarro; Luca Antonioli; Matteo Fornai; Corrado Blandizzi; Marco Tuccori
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

2.  Comparison of Neonatal Abstinence Syndrome Manifestations in Preterm Versus Term Opioid-Exposed Infants.

Authors:  Elizabeth Allocco; Marjorie Melker; Florencia Rojas-Miguez; Caitlin Bradley; Kristen A Hahn; Elisha M Wachman
Journal:  Adv Neonatal Care       Date:  2016-10       Impact factor: 1.968

Review 3.  Modeling prenatal opioid exposure in animals: Current findings and future directions.

Authors:  Elizabeth M Byrnes; Fair M Vassoler
Journal:  Front Neuroendocrinol       Date:  2017-09-28       Impact factor: 8.606

4.  Neonatal abstinence syndrome and early childhood morbidity and mortality in Washington state: a retrospective cohort study.

Authors:  C E Witt; K E Rudd; P Bhatraju; F P Rivara; S E Hawes; N S Weiss
Journal:  J Perinatol       Date:  2017-07-06       Impact factor: 2.521

5.  Gestational Age Alters Assessment of Neonatal Abstinence Syndrome.

Authors:  Sasha Amiri; Jayasree Nair
Journal:  Pediatr Rep       Date:  2022-01-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.